AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25622197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia (CBTI-BP)
Number of subjects: 58
Study 25622197 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 58
Study 24011524 — intervention group
Group type: EXPERIMENTAL
Intervention: Holladay 1 formula
Number of subjects: 43
Study 24011524 — intervention group
Group type: EXPERIMENTAL
Intervention: SRK/T formula
Number of subjects: 43
Study 24011524 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized constant calculations
Number of subjects: 43
Study 21108620 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (C group, n=20)
Number of subjects: 60
Study 21108620 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine (R group, n=20)
Number of subjects: 60
Study 21108620 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine combined with 1 μg/ml sufentanil (RS group, n=20)
Number of subjects: 60
Study 19476115 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise training (IET) - 15 min interval exercise sessions, 2 times daily for 3 weeks
Number of subjects: 31
Study 19476115 — intervention group
Group type: COMPARATOR
Intervention: Steady state exercise training (SSET) - 5-10 min steady state exercise sessions, 2 times daily for 3 weeks
Number of subjects: 31
Study 17099122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention materials that integrated comparative information on cost, benefits, and quality
Number of subjects: 0
Study 17099122 — intervention group
Group type: COMPARATOR
Intervention: Control materials
Number of subjects: 0
Study 14980921 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend index
Number of subjects: 18
Study 14980921 — intervention group
Group type: COMPARATOR
Intervention: BIS
Number of subjects: 18
Study 11816629 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) levels
Number of subjects: 64
Study 9150587 — intervention group
Group type: EXPERIMENTAL
Intervention: High need for closure
Number of subjects: 0
Study 9150587 — intervention group
Group type: COMPARATOR
Intervention: Low need for closure
Number of subjects: 0
Study 8148355 — intervention group
Group type: EXPERIMENTAL
Intervention: Myristic acid diet
Number of subjects: 59
Study 8148355 — intervention group
Group type: COMPARATOR
Intervention: Palmitic acid diet
Number of subjects: 59
Study 8148355 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid diet
Number of subjects: 59
Study 3207070 — intervention group
Group type: EXPERIMENTAL
Intervention: Plethysmography (PG) after 1 year
Number of subjects: 65
Study 3207070 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography (TG) after 1 year
Number of subjects: 65
Study 3207070 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of PG and TG
Number of subjects: 65
Study 3207070 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining venous obstruction and persistent thermoactivity
Number of subjects: 65
Study 30105966 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based 'School of 5' handwashing campaign
Number of subjects: 676
Study 30105966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 676
Study 28471813 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention targeting cognitive skills to challenge a superior's decision
Number of subjects: 50
Study 28471813 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving general crisis management instruction
Number of subjects: 50
Study 26283655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB) ablation
Number of subjects: 315
Study 26283655 — intervention group
Group type: COMPARATOR
Intervention: Open irrigated radiofrequency (RF) ablation
Number of subjects: 315
Study 23539696 — intervention group
Group type: EXPERIMENTAL
Intervention: Semuloparin (20 mg subcutaneously once daily)
Number of subjects: 100
Study 23539696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23539696 — intervention group
Group type: COMPARATOR
Intervention: Semuloparin and Placebo
Number of subjects: 100
Study 20861846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg on demand 1 hour before sexual activity
Number of subjects: 236
Study 20861846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 18988428 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Regulated Strategy Development Model (n=48, 19 girls and 29 boys)
Number of subjects: 121
Study 18988428 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognitive Model of Sequential Skill Acquisition (n=31, 15 girls and 26 boys)
Number of subjects: 121
Study 18988428 — intervention group
Group type: COMPARATOR
Intervention: Ordinary instruction group (n=32, 9 girls and 23 boys)
Number of subjects: 121
Study 16895956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 4 months
Number of subjects: 18
Study 16895956 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy young subjects)
Number of subjects: 18
Study 14620473 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h dive-PFSI-flight profile
Number of subjects: 102
Study 14620473 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 h dive-PFSI-flight profile
Number of subjects: 102
Study 14620473 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h dive-PFSI-flight profile
Number of subjects: 102
Study 14620473 — intervention group
Group type: COMPARATOR
Intervention: 2 h flight-only control
Number of subjects: 102
Study 14620473 — intervention group
Group type: COMPARATOR
Intervention: 3 h flight-only control
Number of subjects: 102
Study 14620473 — intervention group
Group type: EXPERIMENTAL
Intervention: VGE observed in flights
Number of subjects: 102
Study 11401043 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with asthma
Number of subjects: 236
Study 11401043 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with asthma from single-parent families
Number of subjects: 236
Study 8629878 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (low-dose warfarin [INR <1.5] plus 325 mg/d of enteric-coated aspirin)
Number of subjects: 117
Study 8629878 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose warfarin therapy (INR 2.0 to 3.0)
Number of subjects: 117
Study 8629878 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (325 mg/d of enteric-coated aspirin)
Number of subjects: 117
Study 1280411 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 169
Study 1280411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 169
Study 1280411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 6143709 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 45
Study 6143709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 45
Study 6143709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sulphasalazine and levamisole
Number of subjects: 45
Study 30885078 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous counselling offered by pharmacists
Number of subjects: 88
Study 30885078 — intervention group
Group type: EXPERIMENTAL
Intervention: Mention of sedation as a side-effect
Number of subjects: 88
Study 30885078 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning against driving after taking the medication
Number of subjects: 88
Study 30885078 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning against dealing with hazardous machinery
Number of subjects: 88
Study 30885078 — intervention group
Group type: EXPERIMENTAL
Intervention: Other side-effects counselling
Number of subjects: 88
Study 30102493 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of measles vaccine
Number of subjects: 5084
Study 30102493 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of measles vaccine
Number of subjects: 5084
Study 26909482 — intervention group
Group type: EXPERIMENTAL
Intervention: Humulin N®
Number of subjects: 37
Study 26909482 — intervention group
Group type: EXPERIMENTAL
Intervention: Gansulin
Number of subjects: 37
Study 24559010 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration with plain water or a sports drink during 90 min of spinning exercise
Number of subjects: 21
Study 24559010 — intervention group
Group type: COMPARATOR
Intervention: No fluid intake during 90 min of spinning exercise
Number of subjects: 21
Study 22091926 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress condition (Trier Social Stress Test)
Number of subjects: 0
Study 22091926 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 19243458 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy in smoking cessation
Number of subjects: 0
Study 17594937 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 at 1 microg/kg/day
Number of subjects: 33
Study 17594937 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 at 4 microg/kg/day
Number of subjects: 33
Study 17594937 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 at 8 microg/kg three times per week
Number of subjects: 33
Study 17594937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 14974944 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-MPS 720 mg b.i.d.
Number of subjects: 423
Study 14974944 — intervention group
Group type: COMPARATOR
Intervention: MMF 1000 mg b.i.d.
Number of subjects: 423
Study 11262697 — intervention group
Group type: EXPERIMENTAL
Intervention: MKH glasses (prism glasses)
Number of subjects: 72
Study 11262697 — intervention group
Group type: COMPARATOR
Intervention: Orthoptists' glasses (conventional glasses)
Number of subjects: 72
Study 9676306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Elevated room temperature to 27-28 degrees C with cotton blankets
Number of subjects: 50
Study 9676306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Room temperature maintained at 27-28 degrees C with aluminum blanket
Number of subjects: 50
Study 9676306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Elevated room temperature combined with a convective heating blanket
Number of subjects: 50
Study 9676306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: Room temperature maintained at 22 degrees C with aluminum blanket
Number of subjects: 50
Study 9676306 — intervention group
Group type: COMPARATOR
Intervention: Group 5: Room temperature maintained at 22 degrees C with convective heating device
Number of subjects: 50
Study 7990473 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cue exposure
Number of subjects: 24
Study 7990473 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (water)
Number of subjects: 24
Study 3055362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg twice daily
Number of subjects: 60
Study 3055362 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 60
Study 29654699 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (app) for patient support
Number of subjects: 122
Study 29654699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cal/BD cutaneous foam with app
Number of subjects: 122
Study 29654699 — intervention group
Group type: COMPARATOR
Intervention: No app (control)
Number of subjects: 122
Study 27472921 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor timing parameters
Number of subjects: 0
Study 24378765 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 3
Study 24378765 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 3
Study 24378765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 22554491 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy in polygenic hypercholesterolemia (PH)
Number of subjects: 80
Study 22554491 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy in familial combined hyperlipemia (FCH)
Number of subjects: 80
Study 20597268 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin alone (Group 1)
Number of subjects: 82
Study 20597268 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus aspirin (Group 2)
Number of subjects: 82
Study 20597268 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (both groups)
Number of subjects: 82
Study 18384420 — intervention group
Group type: EXPERIMENTAL
Intervention: PPMQ-R (Patient Perception of Migraine Questionnaire - Revised)
Number of subjects: 1304
Study 18384420 — intervention group
Group type: EXPERIMENTAL
Intervention: PPMQ-R
Number of subjects: 1304
Study 16627141 — intervention group
Group type: EXPERIMENTAL
Intervention: Short hydroxyapatite-coated femoral stem
Number of subjects: 80
Study 16627141 — intervention group
Group type: COMPARATOR
Intervention: Regular hydroxyapatite-coated femoral stem
Number of subjects: 80
Study 16627141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study 12784781 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 3283
Study 12784781 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 3283
Study 10774861 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 0.5% bupivacaine with crystalline corticosteroid
Number of subjects: 50
Study 10774861 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 0.5% bupivacaine with lipoid corticosteroid
Number of subjects: 50
Study 10774861 — intervention group
Group type: COMPARATOR
Intervention: 10 ml 0.5% bupivacaine without corticosteroid
Number of subjects: 50
Study 8741518 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical tooth stimulation
Number of subjects: 11
Study 8741518 — intervention group
Group type: EXPERIMENTAL
Intervention: Preceding tone beep
Number of subjects: 11
Study 1449617 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NaF rinse
Number of subjects: 95
Study 1449617 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% H2O2 rinse with 0.05% NaF
Number of subjects: 95
Study 1449617 — intervention group
Group type: COMPARATOR
Intervention: Control group (1100 ppm F toothpaste only)
Number of subjects: 95
Study 2413761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 32% dextran 70
Number of subjects: 164
Study 2413761 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 164
Study 2413761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal hydrocortisone alone
Number of subjects: 164
Study 2413761 — intervention group
Group type: COMPARATOR
Intervention: Adjunct use of intraperitoneal dextran or hydrocortisone
Number of subjects: 164
Study 30909797 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera-based mirror visual feedback (camMVF)
Number of subjects: 20
Study 30909797 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (CG)
Number of subjects: 20
Study 29316012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 0
Study 29316012 — intervention group
Group type: COMPARATOR
Intervention: Escalated therapy
Number of subjects: 0
Study 27895406 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified dyad criteria (combination of proliferation and VS)
Number of subjects: 147
Study 27895406 — intervention group
Group type: COMPARATOR
Intervention: Inoue's tetrad criteria
Number of subjects: 147
Study 25159313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-thalidomide-dexamethasone (VTD)
Number of subjects: 474
Study 25159313 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide-dexamethasone (TD)
Number of subjects: 474
Study 22542960 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-Based Care (MBC)
Number of subjects: 390
Study 22542960 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 390
Study 20482346 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating bracket (Damon3)
Number of subjects: 43
Study 20482346 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating bracket (SmartClip)
Number of subjects: 43
Study 20482346 — intervention group
Group type: COMPARATOR
Intervention: Conventional bracket (Victory Series)
Number of subjects: 43
Study 18589027 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eating rate
Number of subjects: 30
Study 18589027 — intervention group
Group type: COMPARATOR
Intervention: Quick eating rate
Number of subjects: 30
Study 16365330 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic interference (EMI) present during AED operation
Number of subjects: 19
Study 14645424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal radioactive chromic phosphate (32P)
Number of subjects: 229
Study 14645424 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide‐cisplatin (CP)
Number of subjects: 229
Study 10801758 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (nonionic dimer)
Number of subjects: 856
Study 10801758 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate (low osmolar ionic agent)
Number of subjects: 856
Study 8823693 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (200 mg daily)
Number of subjects: 310
Study 8823693 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg daily)
Number of subjects: 310
Study 8823693 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Number of subjects: 310
Study 8823693 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 310
Study 1481585 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) stimulation test
Number of subjects: 1326
Study 1481585 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine treatment
Number of subjects: 1326
Study 1481585 — intervention group
Group type: COMPARATOR
Intervention: Dopamine agonist therapy
Number of subjects: 1326
Study 1481585 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dopamine agonist trial
Number of subjects: 1326
Study 2934788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 342
Study 31120773 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised Random Gradient (GRG) hyper-heuristic
Number of subjects: 108
Study 31120773 — intervention group
Group type: COMPARATOR
Intervention: Randomised Local Search with different neighbourhood sizes
Number of subjects: 108
Study 31120773 — intervention group
Group type: COMPARATOR
Intervention: Evolutionary Algorithms using standard bit mutation
Number of subjects: 108
Study 30666747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) supplementation, 2 grams per day for 6 weeks
Number of subjects: 46
Study 30666747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30666747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) supplementation
Number of subjects: 46
Study 28355259 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B 0.5 mg/kg
Number of subjects: 50
Study 28355259 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B 1 mg/kg
Number of subjects: 50
Study 25042846 — intervention group
Group type: EXPERIMENTAL
Intervention: yogurt
Number of subjects: 24
Study 25042846 — intervention group
Group type: EXPERIMENTAL
Intervention: 3300 FCC units acid lactase from Aspergillus oryzae
Number of subjects: 24
Study 25042846 — intervention group
Group type: EXPERIMENTAL
Intervention: 9000 FCC units acid lactase from Aspergillus oryzae
Number of subjects: 24
Study 25042846 — intervention group
Group type: EXPERIMENTAL
Intervention: 3300 FCC units lactase plus yogurt culture combined
Number of subjects: 24
Study 25042846 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 25026747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatological patients
Number of subjects: 480
Study 25026747 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after first heart attack
Number of subjects: 480
Study 25026747 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 480
Study 21474838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention aimed at restricting saturated fat and cholesterol intake
Number of subjects: 86
Study 21474838 — intervention group
Group type: COMPARATOR
Intervention: Control group with no special recommendations
Number of subjects: 86
Study 19463377 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg/day
Number of subjects: 153
Study 19463377 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 150 mg/day after switching from 75 mg/day
Number of subjects: 153
Study 19463377 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 153
Study 16509522 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 36
Study 16509522 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I
Number of subjects: 36
Study 16509522 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression model with head circumference as dependent variable
Number of subjects: 36
Study 14984519 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (bolus of 0.2 mg.kg‐1 followed by an infusion of 0.2 mg.kg‐1.h‐1)
Number of subjects: 30
Study 14984519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14984519 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 30
Study 14984519 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin and Placebo
Number of subjects: 30
Study 11107461 — intervention group
Group type: EXPERIMENTAL
Intervention: 1998 Canadian lipid guidelines
Number of subjects: 5900000
Study 11107461 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham risk equations
Number of subjects: 5900000
Study 11107461 — intervention group
Group type: COMPARATOR
Intervention: Risk counting
Number of subjects: 5900000
Study 9077498 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA II (n=240)
Number of subjects: 569
Study 9077498 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA III (n=329)
Number of subjects: 569
Study 9077498 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA IIIa (n=195)
Number of subjects: 569
Study 9077498 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA IIIb (n=134)
Number of subjects: 569
Study 8482443 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day mesalamine
Number of subjects: 310
Study 8482443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310